Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612535 | 0.82 | POLB (0.35) | MAPTMEN1ALDH1A1GAAPKM | |
| SCHEMBL28756114 | 0.78 | GSK3A (0.39) | SRCSYKGSK3AMAPK14MAPT | |
| SCHEMBL689446 | 0.78 | MAPT (0.41) | MAPK14MAPTMEN1ALDH1A1GAA | |
| SCHEMBL18186629 | 0.77 | ALDH1A1 (0.42) | SRCSYKGSK3AMAPK14MAPT | |
| SCHEMBL690781 | 0.77 | MAPK14 (0.38) | SRCSYKGSK3AMAPK14MAPT | |
| SCHEMBL16829453 | 0.77 | GSK3A (0.41) | SRCSYKGSK3AMAPK14MAPT | |
| SCHEMBL16829420 | 0.76 | MAPK14 (0.36) | SRCSYKGSK3AMAPK14MAPT | |
| SCHEMBL690103 | 0.76 | POLB (0.44) | MAPTMEN1ALDH1A1GAAPKM | |
| SCHEMBL16829546 | 0.76 | GSK3A (0.40) | SRCSYKGSK3AMAPK14 | |
| SCHEMBL16829221 | 0.75 | MAPK14 (0.50) | SRCSYKGSK3AMAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717162-A | Urea derivatives as kinase inhibitors | 奥苏拉收购有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-9890185-B2 | Urea derivatives useful as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-20160318958-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083604-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | Respivert Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092423-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318958-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | SYK, UACA, YES1 | SRC 6/4885SYK 1/4885GSK3A 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.